Stock Analiz

Verrica Pharmaceuticals Inc. VRCA

Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026

$3.56Market cap $61M
Open the interactive analysis →

Verrica Pharmaceuticals Inc. (VRCA) is a healthcare company listed in the US with a market value of about $61M. In the twelve months to September 30, 2026 it had revenue of $23M and net income of -$43M, a net margin of -189.2%.

Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -86%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 70% below the current price.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $12M in 2021 to $36M in 2025, growth of about 31.2% a year. It was profitable in 0 of the last 9 years in our data. Its share count rose by 212% over three years (dilution for shareholders). It spends 25% of revenue on research and development.

Score: 1.2 / 5

Value0/5
Future growth4/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2.7
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-28.8%
Shareholder yield0.0%
Intrinsic value vs. price−70%

Growth and quality

Revenue growth (1 yr)370.2%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-586.7%
ROIC (5-yr avg.)-85.7%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 9 years

Fiscal yearTTM202520242023202220212020201920182017
Revenue$23M$36M$8M$5M$9M$12M————
Net income-$43M-$18M-$77M-$67M-$24M-$35M-$43M-$28M-$21M-$4M
Free cash flow—-$18M-$61M-$39M-$19M-$28M-$32M-$28M-$19M—
EPS (diluted)$-2.30$-1.68$-14.78$-14.80$-7.20$-13.00$-17.10$-11.30$-14.10$-15.60
Net margin-189.2%-50.3%-1012.1%-1307.5%-271.1%-292.3%————
ROIC—-38.0%-236.5%-81.3%-40.5%-32.1%-45.2%-36.4%-19.3%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $13.80, 288% above the current price; targets range from $9.00 to $20.00; the consensus rating is “Strong buy”; expected EPS is $-1.89 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Verrica Pharmaceuticals stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 70% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Verrica Pharmaceuticals pay a dividend?

Not currently.

Is Verrica Pharmaceuticals a good stock to buy?

We do not give buy or sell advice. Verrica Pharmaceuticals scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.